T1	p 65 88	severe bronchiectasis .
T2	p 243 270	markers in bronchiectasis .
T3	p 431 489	. Twenty-four patients ( 12 female ; mean age 51 yr ) were
T4	p 506 515	receiving
T5	p 1484 1485	.
T6	i 6 25	Inhaled fluticasone
T7	i 98 120	corticosteroid therapy
T8	i 316 334	placebo-controlled
T9	i 401 412	fluticasone
T10	i 523 572	inhaled fluticasone ( 500 microgram twice daily )
T11	i 581 599	Accuhaler device (
T12	i 609 621	or placebo .
T13	i 826 840	leukotriene B4
T14	i 979 990	fluticasone
T15	i 1007 1018	fluticasone
T16	i 1041 1048	placebo
T17	i 1247 1258	fluticasone
T18	i 1411 1434	inhaled steroid therapy
T19	o 34 61	sputum inflammatory indices
T20	o 229 250	and infective markers
T21	o 649 718	, 24-h sputum volume , sputum leukocyte density , bacterial densities
T22	o 721 768	and concentrations of interleukin ( IL ) -1beta
T23	o 776 821	, tumor necrosis factor-alpha ( TNF-alpha ) ,
T24	o 826 837	leukotriene
T25	o 914 945	in sputum leukocyte density and
T26	o 1125 1135	spirometry
T27	o 1165 1182	adverse reactions
T28	o 1288 1315	sputum inflammatory indices
T29	o 1455 1465	components